INOSR APPLIED SCIENCES 12(3):24-28, 2024 ISSN: 2705-165X
©INOSR PUBLICATIONS INOSR12.3.2428.000
International Network Organization for Scientific Research
https://doi.org/10.59298/INOSRAS/2024/12.3.2428

Nanomedicine and Targeted Drug Delivery: Advances and Challenges

Rukundo Sande Kibuuka

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

Nanomedicine, the application of nanotechnology to medicine, has revolutionized the field by providing novel approaches to diagnosing, treating, and preventing diseases. Among its various applications, targeted drug delivery has emerged as a key area of focus, offering the potential to enhance therapeutic efficacy and minimize side effects by directing drugs specifically to diseased cells or tissues. This review discusses the latest advancements in nanomedicine, particularly in the design and development of nanoscale drug delivery systems such as liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles. We explore the mechanisms of passive and active targeting, as well as stimuli-responsive delivery systems. Clinical applications in cancer therapy, cardiovascular diseases, neurological disorders, and infectious diseases are examined to illustrate the practical impact of these technologies. Furthermore, we address the challenges facing the field, including toxicity and biocompatibility concerns, manufacturing and scalability issues, regulatory and ethical considerations, and the integration of personalized medicine approaches. By providing a comprehensive overview of the current state and future directions of nanomedicine and targeted drug delivery, this review aims to highlight the transformative potential of these technologies in improving patient outcomes and advancing healthcare.

Keywords: Nanomedicine, Targeted drug delivery, Liposomes, Passive targeting, Personalized medicine

INTRODUCTION

Nanomedicine, the application of nanotechnology to the field of medicine, has emerged as a groundbreaking area of research and development, offering innovative solutions for diagnosing, treating, and preventing various diseases. At the heart of nanomedicine lies the concept of targeted drug delivery, a strategy that aims to direct therapeutic agents specifically to diseased cells or tissues[1–3]. This targeted approach has the potential to significantly improve the efficacy of treatments while minimizing adverse side effects, thereby addressing one of the critical limitations of conventional therapies[4]. The advent of nanoscale materials and technologies has opened new avenues for designing drug-delivery systems that can navigate the complex biological environment of the human body with unprecedented precision[4, 5]. These nanoscale carriers, which include liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles, can be engineered to enhance drug solubility, protect therapeutic agents from degradation, and release drugs in a controlled manner at the site of action[6]. Targeted drug delivery leverages two primary mechanisms: passive targeting and active targeting. Passive targeting exploits the enhanced permeability and retention (EPR) effect, which is a phenomenon observed in tumor tissues and areas of inflammation where leaky vasculature allows nanoparticles to accumulate[7, 8]. Active targeting, on the other hand, involves the functionalization of nanoparticles with ligands that specifically bind to receptors on the surface of target cells, thereby enhancing the specificity and uptake of the therapeutic agents. Recent advancements in nanomedicine have demonstrated considerable promise in various clinical applications, including cancer therapy, cardiovascular diseases, neurological disorders, and infectious diseases. For instance, nanoparticle-based formulations of chemotherapeutic drugs have shown improved efficacy and reduced toxicity compared to traditional formulations[9, 10]. Similarly, nanoparticles designed to cross the blood-brain barrier hold the potential for treating central nervous system disorders, a challenge that has long

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

hindered effective drug delivery to the brain. Despite these advancements, several challenges remain in the development and implementation of nanomedicine for targeted drug delivery. Concerns regarding the toxicity and long-term effects of nanomaterials, manufacturing and scalability issues, regulatory and ethical considerations, and the need for personalized medicine approaches are significant hurdles that must be addressed[11, 12]. This review aims to provide a comprehensive overview of the current state of nanomedicine and targeted drug delivery, highlighting recent advancements, clinical applications, and the challenges that lie ahead. By exploring the interplay between nanotechnology and medicine, we seek to underscore the transformative potential of nanomedicine in improving patient outcomes and shaping the future of healthcare.

Types of Nanoscale Drug Delivery Systems

Liposomes: Liposomes are spherical vesicles composed of lipid bilayers that can encapsulate both hydrophilic and hydrophobic drugs. They have been extensively studied for their biocompatibility, ability to protect drugs from degradation, and capacity to enhance drug solubility and stability. Liposomal formulations, such as Doxil (liposomal doxorubicin), have already received FDA approval and are used in clinical practice[13, 14].

Polymeric Nanoparticles: Polymeric nanoparticles are formed from biodegradable polymers like poly (lactic-co-glycolic acid) (PLGA) and polyethylene glycol (PEG). These nanoparticles can be engineered to control drug release profiles, improve drug solubility, and target specific tissues or cells. Their versatility makes them suitable for delivering a wide range of therapeutics, including small molecules, proteins, and nucleic acids[15, 16].

Dendrimers: Dendrimers are highly branched, tree-like macromolecules with multiple surface functional groups that can be modified for drug attachment or targeting purposes. Their well-defined structure and high degree of functionality enable precise control over drug delivery and release. Dendrimers have shown promise in delivering anticancer drugs, gene therapies, and imaging agents.[12, 17]

Inorganic Nanoparticles: Inorganic nanoparticles, such as gold nanoparticles, silica nanoparticles, and quantum dots, offer unique optical, electronic, and magnetic properties that can be harnessed for both therapeutic and diagnostic applications. These nanoparticles can be functionalized with targeting ligands, drugs, and imaging agents, making them suitable for multimodal imaging and theranostic applications[18, 19].

Mechanisms of Targeted Drug Delivery

Passive Targeting: Passive targeting exploits the enhanced permeability and retention (EPR) effect observed in tumor tissues and inflamed areas. The leaky vasculature in these regions allows nanoparticles to accumulate preferentially, leading to higher local drug concentrations. This approach is particularly useful for targeting solid tumors[20, 21].

Active Targeting: Active targeting involves the modification of nanoparticles with ligands, such as antibodies, peptides, or small molecules, that can specifically bind to receptors over-expressed on the surface of target cells. This ligand-receptor interaction enhances the specificity and uptake of nanoparticles by diseased cells, improving therapeutic outcomes [22, 23].

Stimuli-Responsive Delivery: Stimuli-responsive delivery systems are designed to release their payload in response to specific triggers in the target environment, such as pH, temperature, or enzymatic activity. This strategy enables controlled drug release at the site of action, reducing systemic toxicity and improving therapeutic efficacy [24].

Clinical Applications

Cancer Therapy: Nanomedicine has made significant strides in cancer therapy, with numerous nanoparticle-based formulations undergoing clinical trials or already in use. These systems can deliver chemotherapeutic agents more effectively, overcome drug resistance, and reduce side effects. Examples include liposomal formulations of doxorubicin and paclitaxel, as well as polymeric nanoparticles loaded with anticancer drugs.

Cardiovascular Diseases: Nanoparticles are being explored for the treatment of cardiovascular diseases, such as atherosclerosis and myocardial infarction. Targeted delivery of anti-inflammatory drugs, thrombolytic agents, and gene therapies can improve therapeutic outcomes and reduce adverse effects associated with conventional treatments.

Neurological Disorders: The blood-brain barrier (BBB) presents a significant challenge for drug delivery to the brain. Nanoparticles can be engineered to cross the BBB and deliver therapeutic agents for the treatment of neurological disorders, such as Alzheimer's disease, Parkinson's disease, and brain tumors.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Infectious Diseases: Nanomedicine offers new avenues for the treatment of infectious diseases by enhancing the delivery of antibiotics, antivirals, and vaccines. Nanoparticle-based systems can improve drug stability, control release, and target pathogens more effectively, addressing issues of drug resistance and improving patient outcomes.

Challenges and Future Directions

Nanomedicine faces several challenges, including toxicity, biocompatibility, manufacturing, and ethical considerations. Toxicity and long-term effects of nanomaterials require comprehensive studies and standardized testing protocols. Manufacturing and scalability are crucial for maintaining consistency, purity, and quality control. Ethical considerations, such as patient consent and potential unforeseen consequences, must be carefully addressed. The regulatory landscape for nanomedicine is still evolving, and clear guidelines and standards are needed to address unique challenges. Personalized medicine, which integrates nanoparticle-based therapies to individual patients' genetic and molecular profiles, holds great promise for more effective treatments and fewer side effects. Advances in genomics, proteomics, and biomarker discovery will drive this personalized approach.

CONCLUSION

Nanomedicine and targeted drug delivery are rapidly advancing medical science, offering innovative solutions to healthcare challenges. Advances in liposomes, polymeric nanoparticles, dendrimers, and inorganic nanoparticles have improved drug delivery to specific cells or tissues, reducing side effects and improving therapeutic efficacy. Mechanisms like passive targeting and active targeting have shown promise in directing therapeutic agents to diseased sites. Nanomedicine has clinical applications in cancer, cardiovascular diseases, neurological disorders, and infectious diseases. However, challenges remain, including toxicity, manufacturing, scalability, regulatory considerations, and personalized medicine approaches.

REFERENCES

1. Puri, A., Mohite, P., Maitra, S., Subramaniyan, V., Kumarasamy, V., Uti, D.E., Sayed, A.A., El-Demerdash, F.M., Algahtani, M., El-Kott, A.F., Shati, A.A., Albaik, M., Abdel-Daim, M.M., Atangwho, I.J.: From nature to nanotechnology: The interplay of traditional medicine, green chemistry, and biogenic metallic phytonanoparticles in modern healthcare innovation and sustainability. Biomed. Pharmacother. Biomedecine Pharmacother. 170, 116083 (2024). https://doi.org/10.1016/j.biopha.2023.116083
2. Haleem, A., Javaid, M., Singh, R.P., Rab, S., Suman, R.: Applications of nanotechnology in medical field: a brief review. Glob. Health J. 7, 70–77(2023). https://doi.org/10.1016/j.glohj.2023.02.008
3. Priyanka, Abusalah, M.A.H., Chopra, H., Sharma, A., Mustafa, S.A., Choudhary, O.P., Sharma, M., Dhawan, M., Khosla, R., Loshali, A., Sundriyal, A., Saini, J.: Nanovaccines: A game changing approach in the fight against infectious diseases. Biomed. Pharmacother. 167,115597(2023). https://doi.org/10.1016/j.biopha.2023.115597
4. Chehelgerdi, M., Chehelgerdi, M., Allela, O.Q.B., Pecho, R.D.C., Jayasankar, N., Rao, D.P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., Saadh, M.J., Amajd, A., Abo-Zaid, M.A., Castillo-Acobo, R.Y., Ismail, A.H., Amin, A.H., Akhavan-Sigari, R.: Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol. Cancer. 22, 169 (2023). https://doi.org/10.1186/s12943-023-01865-0
5. Boppana, S.H., Kutikuppala, L.V.S., Sharma, S., C, M., Rangari, G., Misra, A.K., Kandi, V., Mishra, S., Singh, P.K., Rabaan, A.A., Mohapatra, R.K., Kudrat-E-Zahan, Md.: Current approaches in smart nano-inspired drug delivery: A narrative review. Health Sci. Rep.7,e2065(2024). https://doi.org/10.1002/hsr2.2065
6. Puccetti, M., Pariano, M., Schoubben, A., Giovagnoli, S., Ricci, M.: Biologics, theranostics, and personalized medicine in drug delivery systems. Pharmacol. Res. 201, 107086 (2024). https://doi.org/10.1016/j.phrs.2024.107086
7. Wu, J.: The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. J. Pers. Med. 11, 771 (2021). https://doi.org/10.3390/jpm11080771
8. Fan, D., Cao, Y., Cao, M., Wang, Y., Cao, Y., Gong, T.: Nanomedicine in cancer therapy. Signal Transduct. Target. Ther. 8, 1–34

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

(2023). https://doi.org/10.1038/s41392-023-01536-y
9. Li, J., Wang, Q., Xia, G., Adilijiang, N., Li, Y., Hou, Z., Fan, Z., Li, J.: Recent Advances in Targeted Drug Delivery Strategy for Enhancing Oncotherapy. Pharmaceutics. 15, 2233(2023). https://doi.org/10.3390/pharmaceutics15092233
10. Gârea, S.A., Voicu, A.I., Iovu, H.: Chapter 14 - Clay–Polymer Nanocomposites for Controlled Drug Release. In: Jlassi, K., Chehimi, M.M., and Thomas,S.(eds.)Clay-Polymer Nanocomposites. pp. 475–509. Elsevier (2017)
11. Kim, J., Ahn, S.I., Kim, Y.: Nanotherapeutics engineered to cross the blood-brain barrier for advanced drug delivery to the central nervous system. J. Ind. Eng. Chem. 73, 8–18 (2019). https://doi.org/10.1016/j.jiec.2019.01.021
12. Mittal, K.R., Pharasi, N., Sarna, B., Singh, M., Rachana, Haider, S., Singh, S.K., Dua, K., Jha, S.K., Dey, A., Ojha, S., Mani, S., Jha, N.K.: Nanotechnology-based drug delivery for the treatment of CNS disorders. Transl. Neurosci. 13,527–546(2022). https://doi.org/10.1515/tnsci-2022-0258
13. Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., Alshaer, W.: Liposomes: structure, composition, types, and clinical applications. Heliyon.8,e09394(2022). https://doi.org/10.1016/j.heliyon.2022.e09394
14. Abbasi, H., Kouchak, M., Mirveis, Z., Hajipour, F., Khodarahmi, M., Rahbar, N., Handali, S.: What We Need to Know about Liposomes as Drug Nanocarriers: An Updated Review. Adv. Pharm. Bull. 13, 7–23 (2023). https://doi.org/10.34172/apb.2023.009
15. Bhardwaj, H., Jangde, R.K.: Current updated review on preparation of polymeric nanoparticles for drug delivery and biomedical applications. Nanotechnol. 2, 100013 (2023). https://doi.org/10.1016/j.nxnano.2023.100013
16. Makadia, H.K., Siegel, S.J.: Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers. 3,1377–1397(2011). https://doi.org/10.3390/polym3031377
17. Kenguva, G., Bandaru, R., Rout, S.R., Greish, K., Kesharwani, P., Dandela, R.: Chapter 10 - Combination drug delivery approaches for cancer therapy. In: Kesharwani, P. (ed.) Combination Drug Delivery Approach as an Effective Therapy for Various Diseases. pp. 213–237. Academic Press (2022)
18. Oehler, J.B., Rajapaksha, W., Albrecht, H.: Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer. J. Pers. Med. 14, 723 (2024). https://doi.org/10.3390/jpm14070723
19. Hu, X., Ha, E., Ai, F., Huang, X., Yan, L., He, S., Ruan, S., Hu, J.: Stimulus-responsive inorganic semiconductor nanomaterials for tumor-specific theranostics. Coord. Chem. Rev. 473,214821(2022). https://doi.org/10.1016/j.ccr.2022.214821
20. Subhan, M.A., Yalamarty, S.S.K., Filipczak, N., Parveen, F., Torchilin, V.P.: Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment. J. Pers. Med. 11, 571 (2021). https://doi.org/10.3390/jpm11060571
21. Shinde, V.R., Revi, N., Murugappan, S., Singh, S.P., Rengan, A.K.: Enhanced permeability and retention effect: A key facilitator for solid tumor targeting by nanoparticles. Photodiagnosis Photodyn. Ther. 39, 102915 (2022). https://doi.org/10.1016/j.pdpdt.2022.102915
22. Bajracharya, R., Song, J.G., Patil, B.R., Lee, S.H., Noh, H.-M., Kim, D.-H., Kim, G.-L., Seo, S.-H., Park, J.-W., Jeong, S.H., Lee, C.H., Han, H.-K.: Functional ligands for improving anticancer drug therapy: current status and applications to drug delivery systems. Drug Deliv.29,1959–1970. https://doi.org/10.1080/10717544.2022.2089296
23. Yan, S., Na, J., Liu, X., Wu, P.: Different Targeting Ligands-Mediated Drug Delivery Systems for Tumor Therapy. Pharmaceutics. 16,248(2024). https://doi.org/10.3390/pharmaceutics16020248
24. Rahim, M.A., Jan, N., Khan, S., Shah, H., Madni, A., Khan, A., Jabar, A., Khan, S., Elhissi, A., Hussain, Z., Aziz, H.C., Sohail, M., Khan, M., Thu, H.E.: Recent Advancements in Stimuli Responsive Drug Delivery Platforms for Active and Passive Cancer Targeting. Cancers. 13,670(2021). https://doi.org/10.3390/cancers13040670

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

CITE AS: Rukundo Sande Kibuuka (2024). Nanomedicine and Targeted Drug Delivery: Advances and Challenges. INOSR APPLIED SCIENCES 12(3):24-28.
https://doi.org/10.59298/INOSRAS/2024/12.3.2428

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.